Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacyResearch in context

Background: Bringing antibodies from pre-clinical studies to human trials requires humanization, but this process may alter properties that are crucial for efficacy. Since pathological tau protein is primarily intraneuronal in Alzheimer's disease, the most efficacious antibodies should work both int...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Erin E. Congdon, Jessica E. Chukwu, Dov B. Shamir, Jingjing Deng, Devyani Ujla, Hameetha B.R. Sait, Thomas A. Neubert, Xiang-Peng Kong, Einar M. Sigurdsson
Format:	Artigo
Język:	Inglês
Wydane:	Elsevier 2019-04-01
Seria:	EBioMedicine
Dostęp online:	http://www.sciencedirect.com/science/article/pii/S2352396419301732
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!